D. E. Shaw & Co., Inc. Enanta Pharmaceuticals Inc Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 501,372 shares of ENTA stock, worth $2.93 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

501,372

Holding current value

$2.93 Million

% of portfolio

0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$10.05 - $16.54 $329,730 - $542,660	-32,809 Reduced 6.14%	501,372 $5.2 Million
Q2 2024 Aug 14, 2024	SELL	$11.43 - $17.02 $412,222 - $613,826	-36,065 Reduced 6.32%	534,181 $6.93 Million
Q1 2024 May 15, 2024	SELL	$10.08 - $17.46 $684,653 - $1.19 Million	-67,922 Reduced 10.64%	570,246 $9.96 Million
Q4 2023 Feb 14, 2024	BUY	$8.18 - $10.78 $2.27 Million - $2.99 Million	277,116 Added 76.75%	638,168 $6.01 Million
Q3 2023 Nov 14, 2023	BUY	$11.09 - $22.13 $3.42 Million - $6.83 Million	308,503 Added 587.08%	361,052 $4.03 Million
Q2 2023 Aug 14, 2023	BUY	$20.68 - $39.85 $1.09 Million - $2.09 Million	52,549 New	52,549 $1.12 Million
Q2 2022 Aug 15, 2022	SELL	$38.13 - $76.93 $52,009 - $104,932	-1,364 Reduced 22.34%	4,741 $224,000
Q1 2022 May 16, 2022	SELL	$56.06 - $74.11 $1.03 Million - $1.36 Million	-18,403 Reduced 75.09%	6,105 $435,000
Q4 2021 Feb 14, 2022	BUY	$60.19 - $97.37 $853,012 - $1.38 Million	14,172 Added 137.11%	24,508 $1.83 Million
Q3 2021 Nov 15, 2021	SELL	$41.02 - $58.65 $590,852 - $844,794	-14,404 Reduced 58.22%	10,336 $587,000
Q2 2021 Aug 16, 2021	SELL	$43.76 - $53.11 $719,589 - $873,340	-16,444 Reduced 39.93%	24,740 $1.09 Million
Q1 2021 May 17, 2021	BUY	$41.69 - $54.95 $791,067 - $1.04 Million	18,975 Added 85.44%	41,184 $2.03 Million
Q4 2020 Feb 16, 2021	SELL	$41.16 - $47.47 $87,135 - $100,493	-2,117 Reduced 8.7%	22,209 $935,000
Q3 2020 Nov 16, 2020	BUY	$43.36 - $53.53 $412,440 - $509,177	9,512 Added 64.21%	24,326 $1.11 Million
Q2 2020 Aug 14, 2020	BUY	$46.37 - $57.58 $312,812 - $388,434	6,746 Added 83.61%	14,814 $744,000
Q4 2019 Feb 14, 2020	SELL	$57.95 - $66.61 $187,120 - $215,083	-3,229 Reduced 28.58%	8,068 $498,000
Q3 2019 Nov 14, 2019	BUY	$60.08 - $88.17 $517,529 - $759,496	8,614 Added 321.06%	11,297 $679,000
Q2 2019 Aug 14, 2019	BUY	$81.3 - $97.35 $218,127 - $261,190	2,683 New	2,683 $226,000
Q1 2019 May 15, 2019	SELL	$69.08 - $105.66 $362,670 - $554,715	-5,250 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$65.41 - $84.65 $78,492 - $101,580	-1,200 Reduced 18.6%	5,250 $372,000
Q3 2018 Nov 14, 2018	SELL	$85.46 - $126.37 $2.21 Million - $3.26 Million	-25,815 Reduced 80.01%	6,450 $551,000
Q2 2018 Aug 14, 2018	BUY	$81.85 - $120.51 $161,571 - $237,886	1,974 Added 6.52%	32,265 $3.74 Million
Q1 2018 May 15, 2018	BUY	$57.91 - $92.15 $979,663 - $1.56 Million	16,917 Added 126.49%	30,291 $2.45 Million
Q4 2017 Feb 14, 2018	SELL	$45.65 - $59.37 $285,677 - $371,537	-6,258 Reduced 31.88%	13,374 $785,000
Q3 2017 Nov 14, 2017	BUY	$37.91 - $46.8 $744,249 - $918,777	19,632	19,632 $919,000

Others Institutions Holding ENTA

# of Institutions

110

Shares Held

21.1M

Call Options Held

4.8K

Put Options Held

4.6K

View Full List

About ENANTA PHARMACEUTICALS INC

Ticker ENTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,724,900
Market Cap $121M
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...

More about ENTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account